Androgen deprivation therapy market seen reaching $11.1 billion by 2030

By AI, Created 10:53 AM UTC, May 20, 2026, /AGP/ – The androgen deprivation therapy market is forecast to grow from $8.31 billion in 2025 to $11.1 billion by 2030, driven by rising prostate cancer cases, new treatment approaches and broader adoption of digital care tools. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Rising prostate cancer diagnoses are expanding demand for androgen deprivation therapy, a core treatment used to slow hormone-sensitive tumor growth. - The market’s projected growth signals more spending on prostate cancer care, especially in advanced and metastatic disease.

What happened: - The androgen deprivation therapy market is expected to rise from $8.31 billion in 2025 to $8.83 billion in 2026. - The market is forecast to reach $11.1 billion by 2030. - The projected CAGR is 6.3% from 2025 to 2026 and 5.9% over the full forecast period to 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region through 2030. - The Business Research Company published the analysis and made a sample report and the full report available online.

The details: - The market’s earlier growth was driven by limited prostate cancer treatment alternatives, continued reliance on traditional surgical methods, slow uptake of injectable therapies, low patient awareness and restricted access to advanced treatment options. - Future growth is expected to be supported by innovations in anti-androgen medications. - Rising investment in gene and immunotherapies is also expected to support the market. - An expanding elderly male population is adding to demand. - Growth in specialty clinics and oncology units inside hospitals is broadening access. - Digital monitoring and telehealth are becoming more common in follow-up care. - Key trends include greater use of LHRH agonists and antagonists. - Combination and targeted therapies are also gaining traction. - Minimally invasive surgeries are part of the expected treatment mix. - Providers are moving toward patient-specific and age-tailored treatment approaches. - Improved monitoring and follow-up care are expected to remain important for prostate cancer patients. - Androgen deprivation therapy reduces or blocks male hormone activity to curb the growth of hormone-sensitive cells. - The treatment is especially relevant in hormone-dependent cancers such as prostate cancer. - Prostate cancer incidence is rising largely because life expectancy is increasing. - Older age remains a major risk factor for prostate cancer. - A January 2025 report from Prostate Cancer UK said prostate cancer diagnoses in England rose from 50,751 in 2022 to 55,033 in 2023. - The broader regional analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - Additional related reports are available for the hormone therapy market, the testosterone replacement therapy market, and the drugs for hormonal replacement therapy market.

Between the lines: - The market outlook reflects both medical need and shifting treatment delivery, with digital care and specialty centers changing how prostate cancer patients are managed. - Faster growth in Asia-Pacific suggests access and diagnosis expansion may be improving outside the largest current market. - The forecast also points to a market moving beyond older surgical and injectable approaches toward more personalized therapy.

What’s next: - The market is likely to keep benefiting from aging populations and higher prostate cancer diagnosis rates. - Adoption of telehealth, monitoring tools and targeted therapies may shape competitive positioning through 2030. - Regional growth patterns will show whether North America’s current lead can hold as Asia-Pacific accelerates.